IQVIA’s Therapeutic Centers of Excellence span 15+ specialties, from oncology and cardiology to rare diseases and cell and gene therapy, supporting end-to-end clinical development. With 200+ cell and gene therapy trials in 70+ countries over five years, IQVIA has contributed to ~70% of FDA-approved drugs since 2016, including 80% of genetic disease therapies. Their teams have authored 4,000+ publications and supported 46 oncology approvals across 14 indications (2020–2023). Leveraging a network of 1,400+ partner sites worldwide, IQVIA drives breakthroughs in high-prevalence and rare diseases, accelerating therapies that redefine standards of care.

Join for free to read